INTI has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
INTI has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Inhibitor Therapeutics's yield on cost for the quarter that ended in Sep. 2024 was 0.00.
The historical rank and industry rank for Inhibitor Therapeutics's 5-Year Yield-on-Cost % or its related term are showing as below:
For the Biotechnology subindustry, Inhibitor Therapeutics's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Inhibitor Therapeutics's 5-Year Yield-on-Cost % distribution charts can be found below:
* The bar in red indicates where Inhibitor Therapeutics's 5-Year Yield-on-Cost % falls into.
Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.
Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.
Therefore, Yield-on-Cost of Inhibitor Therapeutics is calculated as
Yield-on-Cost | = | Dividend Yield % | * | (1 | + | Dividend Growth Rate)^5 |
Inhibitor Therapeutics (OTCPK:INTI) 5-Year Yield-on-Cost % Explanation
Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.
Thank you for viewing the detailed overview of Inhibitor Therapeutics's 5-Year Yield-on-Cost % provided by GuruFocus.com. Please click on the following links to see related term pages.
Black Robe Capital Llc | 10 percent owner | 900 WEST PLATT STREET SUITE 200, TAMPA FL 33606 |
Ronald E Osman Irrevocable Trust Iii | 10 percent owner | 1602 WEST KIMMEL, P.O. BOX 939, MARION IL 62959 |
Ronald E Osman | director, 10 percent owner | 1602 KIMMEL STREET, MARION IL 62959 |
Donovan James Joseph Iii | 10 percent owner | C/O TPB 2012 LLC 12412 POWERSCOURT DR, SUITE 35, SAINT LOUIS MO 63131 |
Tpb 2012 Llc | 10 percent owner | 12412 POWERSCOURT DRIVE SUITE 35, SAINT LOUIS MO 63131 |
Michelle Yanez | director | 449 S. 12TH STREET UNIT 1705, TAMPA FL 33602 |
Niraj Vasisht | director | C/O BIODELIVERY SCIENCES INTERNATIONAL, 4131 PARK LAKE AVE., SUITE 225, RALEIGH NC 27612 |
James A Mcnulty | 10 percent owner, officer: See Remarks | C/O CV SCIENCES, INC., 2688 S. RAINBOW BLVD., SUITE B, LAS VEGAS NV 89146 |
Mayne Pharma International Pty Ltd | 10 percent owner | 1538 MAIN NORTH ROAD, SALISBURY SOUTH, SA C3 5106 |
Mayne Pharma Ventures Pty Ltd | 10 percent owner | 1538 MAIN NORTH ROAD, SALISBURY SOUTH, SA C3 5106 |
Mayne Pharma Group Ltd | 10 percent owner | 1538 MAIN NORTH ROAD, SALISBURY SOUTH, SA C3 5106 |
Garrison J. Hasara | officer: CFO and Treasurer | 324 S. HYDE PARK AVENUE, SUITE 350, TAMPA FL 33606 |
Debra Peattie | director | 4830 W. KENNEDY BLVD., SUITE 600, TAMPA FL 33609 |
Robert Daniel Martin | director | C/O HEDGEPATH PHARMACEUTICALS, INC., 324 SOUTH HYDE PARK AVENUE, SUITE 350, TAMPA FL 33606 |
E. Brendan Magrab | director, officer: Chairman of the Board | C/O HEDGEPATH PHARMACEUTICALS, INC., 324 SOUTH HYDE PARK AVENUE, SUITE 350, TAMPA FL 33606 |
From GuruFocus
By PRNewswire PRNewswire • 11-25-2019
By PRNewswire PRNewswire • 10-09-2018
By PRNewswire PRNewswire • 05-21-2018
By Marketwired • 08-22-2024
By PRNewswire PRNewswire • 10-11-2018
By PRNewswire PRNewswire • 05-14-2018
By PRNewswire PRNewswire • 01-22-2020
By PRNewswire PRNewswire • 04-15-2019
By ACCESSWIRE AccessWire • 04-12-2019
By PRNewswire PRNewswire • 05-06-2019
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.